| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BLFS | Common Stock | Options Exercise | $19K | +10K | +3.06% | $1.90* | 337K | Apr 11, 2022 | Direct | |
| transaction | BLFS | Common Stock | Sale | -$196K | -10K | -2.97% | $19.55 | 327K | Apr 11, 2022 | Direct | F1, F2 |
| transaction | BLFS | Common Stock | Options Exercise | +57.7K | +17.65% | 385K | Apr 12, 2022 | Direct | F3 | ||
| transaction | BLFS | Common Stock | Options Exercise | $19K | +10K | +2.6% | $1.90* | 395K | Apr 13, 2022 | Direct | |
| transaction | BLFS | Common Stock | Sale | -$191K | -10K | -2.53% | $19.06 | 385K | Apr 13, 2022 | Direct | F1, F4 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BLFS | Employee Stock Option | Options Exercise | $0 | -10K | -12.5% | $0.00 | 70K | Apr 11, 2022 | Common Stock | 10K | $1.90 | Direct | F5 |
| transaction | BLFS | Restricted Stock Award | Options Exercise | $0 | -57.7K | -100% | $0.00* | 0 | Apr 12, 2022 | Common Stock | 57.7K | $0.00 | Direct | F3 |
| transaction | BLFS | Employee Stock Option | Options Exercise | $0 | -10K | -14.29% | $0.00 | 60K | Apr 13, 2022 | Common Stock | 10K | $1.90 | Direct | F5 |
| Id | Content |
|---|---|
| F1 | The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of May 21, 2021. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.13 to $19.98, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| F3 | The restricted stock was granted pursuant to BioLife Solutions 2013 Performance Incentive Plan (as amended). In accordance with the terms of the grant, the restricted stock vested as to 200% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2020 through December 31, 2021 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| F4 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.61 to $19.28, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| F5 | On March 15, 2016, the reporting person was granted an option to purchase 100,000 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. |